- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04119908
Videomicroscopy for the Prediction of Bleeding in Constitutional Haemorrhagic Diseases (VIDEO-BLEED)
September 1, 2023 updated by: University Hospital, Lille
Interest of Sublingual Videomicroscopy for the Prediction of Bleeding in Von Willebrand Disease and Other Constitutional Haemorrhagic Diseases
In Willebrand disease, there is currently no test available to identify non-invasively patients with a high risk of bleeding from angiodysplasias The study propose to use a sublingual capillary bed analysis by video-microscopy, a sensitive, reproducible and non-invasive technique, to assess whether sublingual capillary density is predictive of hemorrhagic risk for patients with von Willebrand disease.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
400
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Antoine Rauch, MD,PhD
- Phone Number: +33 3 20445962 (poste 29673)
- Email: antoine.rauch@chru-lille.fr
Study Locations
-
-
Nord
-
Lille, Nord, France, 59000
- Recruiting
- CHU de Lille
-
Principal Investigator:
- Antoine RAUCH, MD
-
Contact:
- Antoine Rauch, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Adult patient with a significant form of von Willebrand disease (according to the inclusion criteria of the Willebrand Disease French Reference Center), a Glanzmann Thrombasthenia, a moderate to severe Haemophilia A or a woman carrying the hemophilia gene
- Social insured patient
Exclusion Criteria:
- Minor patient
- Refusal of consent
- Person benefiting from a system of legal protection
- Pregnant patient
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients with haemorrhagic disease
Patients with von Willebrand disease or Patients with Glanzmann Thrombasthenia
|
Measurement of sublingual capillary density by video microscopy
Collection of citrate tubes of 5 mL at baseline and at 36 months
|
Other: Control group
Patients with moderate or severe hemophilia A or women carrying the hemophilia gene
|
Measurement of sublingual capillary density by video microscopy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
area under the ROC curve from Sublingual capillary density to inclusion for the event "existence of at least a clinically significant haemorrhage"
Time Frame: at 3 years
|
at 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sublingual capillary density
Time Frame: At baseline
|
To compare the sublingual capillary density of patients with von Willebrand disease to that of 3 other groups of patients:
|
At baseline
|
qualitative abnormalities of sublingual capillaries (capillary haemorrhage, capillary dystrophy)
Time Frame: At baseline and at 3 years
|
presence or absence of qualitative abnormalities
|
At baseline and at 3 years
|
delta of Sublingual capillary density increase
Time Frame: between inclusion and end of study (at 3 years)
|
between inclusion and end of study (at 3 years)
|
|
ISTH-BAT haemorrhagic score (International Society on Thrombosis and Hemostasis - Bleeding Assessment Tool)
Time Frame: At baseline, at 3 years
|
ISTH-BAT is a questionnaire minimum score ranges from 0 to 10 whereas maximum score ranges from 20 to 30
|
At baseline, at 3 years
|
delta of increase of ISTH-BAT haemorrhagic score
Time Frame: between inclusion and end of study (at 3 years)
|
ISTH-BAT is a questionnaire minimum score ranges from 0 to 10 whereas maximum score ranges from 20 to 30
|
between inclusion and end of study (at 3 years)
|
plasma levels of proangiogenic markers
Time Frame: at inclusion and end-of-study visits(at 3 years)
|
dosage of angiopoietin-1, angiopoetin-2 (pg/mL) measured by ELISA
|
at inclusion and end-of-study visits(at 3 years)
|
plasma levels of galectine
Time Frame: at inclusion and end-of-study visits(at 3 years)
|
galectin-1 and galectin-3 measured by ELISA
|
at inclusion and end-of-study visits(at 3 years)
|
plasma levels of VEGF
Time Frame: at inclusion and end-of-study visits(at 3 years)
|
Concentration (pg/ml) of Vascular Endothelial Growth Factor (VEGF) in blood measured by ELISA
|
at inclusion and end-of-study visits(at 3 years)
|
delta of increase in plasma levels of all proangiogenic markers
Time Frame: At inclusion and end of study (at 3 years)
|
At inclusion and end of study (at 3 years)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Antoine Rauch, MD,PhD, University Hospital, Lille
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 24, 2023
Primary Completion (Estimated)
May 24, 2028
Study Completion (Estimated)
May 24, 2028
Study Registration Dates
First Submitted
October 7, 2019
First Submitted That Met QC Criteria
October 7, 2019
First Posted (Actual)
October 9, 2019
Study Record Updates
Last Update Posted (Actual)
September 7, 2023
Last Update Submitted That Met QC Criteria
September 1, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019_05
- 2019-A01601-56 (Other Identifier: ID-RCB number,ANSM)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glanzmann Thrombasthenia
-
UMC UtrechtNot yet recruitingGlanzmann Thrombasthenia
-
Rockefeller UniversityNational Heart, Lung, and Blood Institute (NHLBI)RecruitingGlanzmann ThrombastheniaUnited States
-
HaemnetHemab ApSCompletedGlanzmann ThrombastheniaUnited Kingdom
-
University Hospital, BordeauxCompleted
-
University Hospital, BordeauxCompletedGlanzmann ThrombastheniaFrance
-
Hemab ApSRecruitingGlanzmann ThrombastheniaUnited States, Belgium, France, Italy, Netherlands, United Kingdom
-
AryoGen Pharmed Co.CompletedFactor VII Deficiency | Hemophilia A With Inhibitor | Hemophilia B With Inhibitor | Glanzmann's ThrombastheniaIran, Islamic Republic of
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Glanzmann's DiseaseJapan
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Glanzmann's DiseaseSpain, Bulgaria, Pakistan, Belgium, Germany, France, United Kingdom, Italy, Hungary, Netherlands, United States, Algeria, Austria, Sweden, Switzerland
-
Catalyst BiosciencesTerminatedFactor VII Deficiency | Hemophilia A With Inhibitor | Glanzmann ThrombastheniaUnited States, India, Italy, Russian Federation, Ukraine
Clinical Trials on Sublingual videomicroscopy
-
Medical Centre LeeuwardenCompleted
-
Szeged UniversityNot yet recruiting
-
Andrea Campos-SerraCorporacion Parc TauliCompleted
-
Medical University of LodzUnknownAllergic Rhinitis | Bronchial AsthmaPoland
-
Stallergenes GreerCompletedPrimary DiseaseFrance, Italy, Spain
-
Stallergenes GreerCompletedAllergic Rhinitis Due to Grass PollensUnited States
-
ALK-Abelló A/SActive, not recruitingAllergic Rhinitis Due to Dermatophagoides Farinae | Allergic Rhinitis Due to Dermatophagoides Pteronyssinus | Allergic Rhinitis Due to House Dust MiteSpain, Russian Federation, United States, Poland, Bulgaria, Canada, France, Germany, Lithuania, Slovakia, Ukraine
-
Bispebjerg HospitalLund University; University of Copenhagen; ALK-Abelló A/SCompletedThe Effect of Allergen Immunotherapy on Anti-viral Immunity in Patients With Allergic Asthma (VITAL)Allergic Asthma Due to Dermatophagoides PteronyssinusDenmark
-
Inmunotek S.L.CompletedRhinitis | RhinoconjunctivitisSpain
-
HAL AllergyCompletedBirch Pollen Allergy | Seasonal Rhinitis and/or RhinoconjunctivitisGermany